Sanofi

SNY, SNYNF · Pharmaceutical Preparations · EDGAR filings ↗

Grade

B78

Wide-moat diversified pharma/vaccines leader with solid—but not top-decile—returns and a mixed pipeline readout.

Strengths

Strong ROA 6.2% (90th), ROE 10.9% (76.8th), interest coverage 11.3x (90th)
Net income growth 57.8% (77.7th); deep pipeline with several positive Phase 3 wins (isatuximab SC, iGlarLixi, RIV4 9-17, HS)
Durable IP/scale and large cash balance (98th)

Risks

Several clear pipeline misses/terminations (RIPK1 MS, pediatric flu 3-8, SLE, amcenestrant)
Significant product-liability litigation (Zantac, Taxotere, Depakine, Talc) and pricing/340B exposure
Weak quick ratio (0.73, 13.7th)

Notable findings

Strong balance sheetStrong balance sheet — $9.0B cash & investments
Notable holderHeld by 4 notable fund(s): FMR LLC, GOLDMAN SACHS GROUP INC, CITADEL ADVISORS LLC +1 more (as of 2026-03-31)
Trial readout soonUpcoming trial readout ~2026-03-31 — PHASE2 · Chronic Rhinosinusitis Without Nasal Polyps

Key metrics

Return on equity

10.9%

Return on assets

6.2%

ROIC

5.5%

Net-income growth

57.8%

Debt / equity

0.3×

Interest coverage

11.3×

Current ratio

1.1×

Tangible book value

$35.7B

Cash & investments

$9.0B

Clinical trials

Trial	Title	Phase	Status	Primary completion
NCT07360080 ↗	Long-Term Outcomes of Teplizumab in Routine Clinical Care Type 1 Diabetes	—	Recruiting	2035-10-29
NCT03687359 ↗	Observational Evaluation of Atopic Dermatitis in Pediatric Patients Dermatitis Atopic	—	Active Not Recruiting	2035-07-23
NCT00567073 ↗	Pompe Pregnancy Sub-Registry Glycogen Storage Disease Type II (GSD-II), Pompe Disease (Late-onset)	—	Recruiting	2034-01-31
NCT00358943 ↗	International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry Gaucher Disease, Cerebroside Lipidosis Syndrome	—	Recruiting	2034-01-31
NCT00196742 ↗	Fabry Disease Registry & Pregnancy Sub-registry Fabry Disease	—	Recruiting	2034-01-31
NCT00231400 ↗	Pompe Disease Registry Protocol Glycogen Storage Disease Type II, Pompe Disease	—	Recruiting	2034-01-31
NCT07290803 ↗	This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment Atopic Dermatitis	—	Recruiting	2034-01-30
NCT01736592 ↗	Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration Stargardt's Disease	PHASE2	Active Not Recruiting	2033-08-29
NCT05734521 ↗	Avalglucosidase Alfa Pregnancy Study Pompe Disease, Pregnancy	—	Recruiting	2032-10-31
NCT06684314 ↗	A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in Taiwan Hemophilia A	—	Recruiting	2031-08-28
NCT02065011 ↗	A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B Usher's Syndrome	PHASE2	Active Not Recruiting	2031-06-13
NCT05769777 ↗	Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis Dermatitis Atopic	PHASE2	Active Not Recruiting	2031-06-11
NCT06630806 ↗	A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma Plasma Cell Myeloma Refractory	PHASE1	Recruiting	2031-05-16
NCT06914908 ↗	Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study Chronic Rhinosinusitis With Nasal Polyps	PHASE2	Enrolling By Invitation	2031-01-29
NCT06609239 ↗	Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma Asthma	PHASE2	Enrolling By Invitation	2031-01-20
NCT04270409 ↗	Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma Plasma Cell Myeloma	PHASE3	Active Not Recruiting	2030-10-14
NCT07380711 ↗	Long-term Real-world Study of Dupilumab in COPD : Patient Characteristics, Safety and Patient-reported Outcomes Chronic Obstructive Pulmonary Disease COPD	—	Recruiting	2030-08-14
NCT07222189 ↗	A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS) Colitis Ulcerative, Crohn's Disease	PHASE2	Enrolling By Invitation	2030-05-10
NCT05972629 ↗	A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With Phenylketonuria Phenylketonuria	PHASE1/PHASE2	Active Not Recruiting	2030-04-02
NCT07190209 ↗	Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype Chronic Obstructive Pulmonary Disease	PHASE3	Recruiting	2029-11-27

Source: ClinicalTrials.gov (U.S. NIH) · active studies first.

Supply chain

Customers (4)

Suppliers (6)

Named in the 10-K; linked when we track them.

Recent filings

Form	Filed	Period	Accession
20-F	2026-02-17	2025-12-31	0001628280-26-008403 ↗
20-F	2025-02-13	2024-12-31	0001121404-25-000010 ↗
20-F	2024-02-23	2023-12-31	0001121404-24-000009 ↗
20-F	2023-02-24	2022-12-31	0001121404-23-000008 ↗
20-F	2022-02-23	2021-12-31	0001121404-22-000007 ↗
20-F	2021-03-04	2020-12-31	0001121404-21-000004 ↗
20-F	2020-03-05	2019-12-31	0001121404-20-000006 ↗
20-F	2019-03-08	2018-12-31	0001193125-19-068926 ↗
20-F	2018-03-07	2017-12-31	0001193125-18-073307 ↗
20-F	2017-03-03	2016-12-31	0001193125-17-069257 ↗
20-F	2016-03-04	2015-12-31	0001193125-16-493072 ↗
20-F	2015-03-11	2014-12-31	0001047469-15-001974 ↗